Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligible
Patients must not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the principal investigator (PI); patients on greater than or equal to  anti-thrombotic agents, including but not limited to anti-platelet agents (nonsteroidal anti-inflammatory drugs [NSAIDS]/aspirin, clopidogrel), heparin, low molecular weight heparin, warfarin and a direct thrombin inhibitor will be excluded
Current necessity for full-dose anticoagulation with warfarin or its equivalent (i.e. unfractionated and/or low molecular weight heparin)
Treatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar agents for therapeutic purposes;
Therapeutic anticoagulation is allowed; the participant must be on a stable dose of anticoagulant medication (warfarin, or low molecular weight heparin [LMWH]) prior to study entry
Current and continuing anticoagulation with warfarin sodium (Coumadin, heparin, low-molecular weight heparin, Clopidogrel bisulfate (Plavix),or equivalent. (Unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or for marker placement).
Patients who are on therapeutic anticoagulation with warfarin; patients on therapeutic doses of with low molecular weight heparins are eligible
Patients must not be on therapeutic anticoagulation (Warfarin [coumadin] and/or low molecular weight heparin are prohibited). Prophylactic anticoagulation (i.e. intraluminal heparin) of venous or arterial access devices is allowed.
Patients who are currently receiving therapeutic anti-coagulation with heparin, low-molecular weight heparin or Coumadin are not eligible for this trial
Patients on therapeutic doses of Coumadin (>  mg daily); the use of therapeutic or prophylactic low molecular weight heparin or fragmin is permitted
Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity or to have a biopsy if needed).
Current and continuing anticoagulation with warfarin sodium (coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (plavix), or equivalent (unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or place markers)
Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists or any form of anticoagulation including low molecular weight heparin
Subjects who require therapeutic anticoagulation or anti-platelet therapy\r\n* Low dose aspirin (=<  mg/day) is allowed\r\n* Prophylactic doses of low molecular weight heparin (LMWH) are allowed if approved by study chair or designee
Therapeutic anticoagulation with drugs requiring international normalized ratio (INR) monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day)
Current anticoagulation therapy with therapeutic doses of warfarin (low-dose warfarin =<  mg/day or low molecular-weight heparin are permitted
Subjects must not be on full dose oral anticoagulation such as warfarin. Low dose warfarin and prophylactic as well as therapeutic low molecular weight heparin are allowable.
Patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose
History of thromboembolic event or other condition currently requiring anticoagulation with warfarin (coumadin); patients who are treated with low molecular weight heparin or fondaparinux are eligible
Requirement for anti-coagulation with Coumadin, low molecular weight heparin and anti-thrombin inhibitors will be accepted if anticoagulation has been stable for at least  weeks and no recent history of prior bleeding complications
Activated partial thromboplastin time (aPTT) =< . x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin) (obtained within  days prior to first study treatment)
Patients may not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the P.I.; patients who are on greater than or equal to  anti-thrombotic agents, including but not limited to anti-platelet agents (non-steroidal anti-inflammatory drugs [NSAIDs]/aspirin, clopidogrel), heparin, low molecular weight heparin (LMWH), warfarin, and a direct thrombin inhibitor, will be excluded
Subjects receiving any vitamin K antagonists (VKAs) prior to randomization or receiving more than  hours treatment with LMW(low molecular weight Heparin) in therapeutic doses prior to randomization;
Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < mg per day)
Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low molecular weight heparin and heparin line flush allowed).
Anticoagulation therapy (within  days of Study Day ), except low molecular weight heparins or low dose aspirin.
The patient is receiving therapeutic anticoagulation with warfarin, low molecular weight heparin, or similar agents; patients receiving prophylactic, low-dose anticoagulation therapy are eligible provided that the coagulation parameters defined in the inclusion criteria (INR =< . or PT =< . x ULN and PTT/aPTT =< . x ULN)
Receiving therapeutic anticoagulation (Coumadin or low molecular weight heparin, heparin, apixaban, dabigatran, rivaroxaban, warfarin)
Within  months of registration: Activated partial thromboplastin time (aPTT) =< . x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Subject is receiving therapeutic anticoagulation therapy; low dose anti-coagulation (e.g., low dose heparin or warfarin) for catheter prophylaxis will be permitted; use of aspirin for treatment of atrial fibrillation will also be permitted
Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligible
Receiving therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg once daily [QD])
Partial thromboplastin time (PTT) =< institution's upper limit of normal, unless receiving therapeutic low molecular weight heparin
Patients requiring use of warfarin for therapeutic purposes; subcutaneous heparin or fractionated heparin products are permitted if the goal is not to achieve full-dose systemic anticoagulation
Currently receiving anticoagulation with therapeutic doses of warfarin (low-molecular weight heparin is permitted)
Partial thromboplastin time =< institutional upper limit of normal, unless receiving therapeutic low molecular weight heparin
Therapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparin
Within  days prior to registration: Partial thromboplastin time (PTT) =< institutions ULN, unless receiving therapeutic low molecular weight heparin
Receiving therapeutic anticoagulation (Coumadin or low molecular weight heparin)
Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders; patients on anticoagulation with low molecular weight heparin are allowed
Subjects on warfarin. Prophylactic anticoagulation with low molecular weight heparin\n             is allowed
Patients who are currently receiving therapeutic anti-coagulation with heparin, low-molecular weight heparin or Coumadin are not eligible for this trial
Patients requiring chronic anticoagulation with warfarin are excluded; patients treated with low molecular weight heparin or unfractionated heparin are eligible if on a stable dose without evidence of clinically significant bleeding for at least  weeks prior to enrollment
Oral anticoagulants such as warfarin are cytochrome P family , subfamily C, polypeptide  (CYPC) substrates and, as such, no interaction with everolimus is expected; anticoagulation with Coumadin is allowed if target INR is =< . and stable for >  weeks; anticoagulation with low-molecular-weight heparin (LMWH) is allowed
Ongoing treatment with therapeutic doses of warfarin or low molecular weight heparin (low dose warfarin up to  mg orally [PO] daily or use of subcutaneous low molecular weight heparin for thromboembolic prophylaxis is allowed)
Anticoagulation/antiplatelet therapy within  days of Cycle  Day , including low molecular weight heparin, or warfarin.
Anticoagulation/antiplatelet therapy within  days of CD, including acetylsalicylic acid, low molecular weight heparin, or warfarin
patients on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and or per local standard of care) during vaccination and nephrectomy, is not an option
Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, warfarin and others) are not eligible
Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day)
Therapeutic anticoagulation (e.g., warfarin, heparin) must be discontinued and coagulation parameters must be normalized prior to the first dose of GSK. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices.
No therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day); no history of clinically significant hemorrhagic or thromboembolic event in the past  months
Patients receiving warfarin or other vitamin K antagonists; however, if therapeutic anticoagulation is necessary, low molecular weight heparin (LMWH) is the anticoagulant of choice
Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.
Patients on therapeutic anticoagulation, with heparin (or low-molecular weight heparin), warfarin, or a direct thrombin inhibitor as the safety of concurrent administration of curcumin has not been established
Patients receiving therapeutic doses of warfarin are not eligible for participation; Note: Patients with a need for therapeutic anticoagulation should be given low molecular weight heparin or other non-warfarin product
Patients requiring full therapeutic anticoagulation with warfarin are ineligible because therapy on this trial may result in frequent and recurrent thrombocytopenia; full therapeutic anticoagulation with heparin, low molecular weight heparin, or direct factor Xa inhibitor is permitted
Patients requiring full therapeutic anticoagulation including warfarin, heparin, low-molecular weight heparin, or direct factor Xa inhibitor are ineligible because therapy on this trial may result in frequent and recurrent thrombocytopenia; patients requiring prophylactic dose anticoagulation may be eligible after discussion with the principal investigator
Patients on therapeutic anticoagulation with low molecular weight heparins, fondaparinux, rivaroxaban or warfarin are eligible, provided that they are on a stable dose of anticoagulants; patients who are currently receiving antiplatelet therapy of prasugrel or clopidogrel or antiaggregation agents (e.g., eptifibatide, epoprostenol, dipyridamole) or low doses of acetylsalicylic acid (up to  mg daily) are also eligible
Patients requiring warfarin/Coumadin for therapeutic anticoagulation; low molecular weight heparin is allowed
Anti-coagulation at baseline:\r\n* For the first  patients to register to trial, no anti-coagulation is allowed; patients requiring therapeutic anticoagulation with warfarin or therapeutic or prophylactic therapy with a low-molecular weight heparin at baseline are excluded\r\n* For all subsequent patients screened, patients requiring therapeutic anticoagulation with warfarin at baseline are excluded; however, therapeutic or prophylactic therapy with a low-molecular weight heparin at baseline is acceptable
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon), direct thrombin inhibitors, direct factor Xa inhibitors or heparin or low-molecular weight heparins at therapeutic doses
This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low molecular weight heparin or warfarin) should be on a stable dose.
Therapeutic anticoagulation (e.g. warfarin, heparin, etc.) must be stopped at least  days prior to the first dose of MK-. Low-dose low molecular weight heparin (LMWH) is permitted
Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin and oral Xa inhibitors are allowed.
Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day)
Participants who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin
Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.
No active anticoagulation within  days of study Day ; including acetylsalicylic acid, low molecular weight heparin, or warfarin.
Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin
Current use of therapeutic warfarin. NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permitted
Current use of therapeutic warfarin. Low-molecular-weight heparin and prophylactic low-dose warfarin are permitted
Therapeutic anticoagulation (except for low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day)
History of thromboembolic event or other condition requiring ongoing use of anticoagulation either with warfarin or low molecular-weight heparin. Note: Occlusion of a central line is not exclusion.
Patients who are on anticoagulation medication that may not be safely held for the procedure (>=  days for antiplatelet agents and warfarin; >=  hours for low-molecular weight heparin formulations) will be excluded
Patients requiring therapeutic anticoagulation (e.g., warfarin, dabigatran, heparin, or low molecular weight heparins [Lovenox, dalteparin])
Patients receiving therapeutic anticoagulation should be switched to low molecular weight heparin (LMWH) before the first cycle of obinutuzumab
Thrombologic event within  weeks of treatment start date, unless stable on anticoagulation with low molecular weight heparin (LMWH) or Factor Xa inhibitor for at least  weeks
Therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <  mg per day)
Diagnosis of symptomatic venous thromboembolism requiring therapeutic-dose anticoagulation (unfractionated or low-molecular weight heparin or oral anticoagulants) throughout the period of hematopoietic recovery
No therapeutic heparin (including low molecular weight) or Coumadin use
Therapeutic dose anticoagulation with warfarin, low molecular-weight heparin, or similar agents.
Obtained within  days prior to registration: Activated partial thromboplastin time (aPTT) =< . x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)
Current treatment with anticoagulation such as warfarin or low-molecular-weight heparin.
Anticoagulation: if currently receiving therapeutic anticoagulation with heparin, low-molecular weight heparin, or Coumadin, not eligible